Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 14/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127817 | 0.88 | S1PR4 (0.40) | S1PR4S1PR1S1PR5MAPTGNRHR | |
| SCHEMBL128602 | 0.76 | GNRHR (0.44) | GNRHR | |
| SCHEMBL16986848 | 0.74 | CASR (0.40) | S1PR4S1PR1S1PR5MAPTGNRHR | |
| SCHEMBL4770813 | 0.73 | L3MBTL1 (0.61) | S1PR4S1PR1S1PR5MAPTGNRHR | |
| SCHEMBL5754941 | 0.72 | GNRHR (0.65) | GNRHR | |
| SCHEMBL21693603 | 0.69 | GNRHR (0.45) | GNRHRKMT2A | |
| SCHEMBL127368 | 0.69 | TYMP (0.45) | S1PR4S1PR1S1PR5MAPTKMT2A | |
| SCHEMBL172575 | 0.69 | MAPT (0.44) | MAPTKMT2ALMNA | |
| SCHEMBL23595095 | 0.68 | GNRHR (0.49) | GNRHR | |
| SCHEMBL25111711 | 0.67 | GNRHR (0.61) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050234082-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| US-6872728-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6608197-B2 | Aminoalkyl-substituted pyrimidones | NEUROCRINE BIOSCIENCES, INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1255738-A2 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020132820-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2001055119-A2 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234082-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | S1PR4 492/4885S1PR1 453/4885S1PR5 389/4885 |
| US-20020132820-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | S1PR4 401/4885S1PR1 430/4885S1PR5 309/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | S1PR4 492/4885S1PR1 453/4885S1PR5 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.